| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for E19 from our risk checks.
Centrum Medyczne ENEL-MED S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł4.40 |
| 52 Week High | zł4.58 |
| 52 Week Low | zł4.22 |
| Beta | 0.044 |
| 11 Month Change | 1.85% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -0.45% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| E19 | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -0.5% | 1.3% | 2.8% |
| 1Y | n/a | 0.7% | 8.6% |
Return vs Industry: Insufficient data to determine how E19 performed against the German Healthcare industry.
Return vs Market: Insufficient data to determine how E19 performed against the German Market.
Price Volatility
| E19 volatility | |
|---|---|
| E19 Average Weekly Movement | 3.4% |
| Healthcare Industry Average Movement | 3.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: E19 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine E19's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 1,179 | Jacek Rozwadowski | enel.pl |
Centrum Medyczne ENEL-MED S.A. provides various medical services in Poland. It offers specialist consultation, dentistry, orthopedic, infertility treatment, rehabilitation, psychological, diagnostic, magnetic resonance imaging, endoscopic examination, x-ray, and laboratory testing services. It also provides vaccination for adult and children.
Centrum Medyczne ENEL-MED S.A. Fundamentals Summary
| E19 fundamental statistics | |
|---|---|
| Market cap | €130.47m |
| Earnings (TTM) | €3.83m |
| Revenue (TTM) | €153.18m |
34.1x
P/E Ratio0.9x
P/S RatioIs E19 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| E19 income statement (TTM) | |
|---|---|
| Revenue | zł654.12m |
| Cost of Revenue | zł618.52m |
| Gross Profit | zł35.60m |
| Other Expenses | zł19.24m |
| Earnings | zł16.36m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Sep 30, 2024
| Earnings per share (EPS) | 0.58 |
| Gross Margin | 5.44% |
| Net Profit Margin | 2.50% |
| Debt/Equity Ratio | 12.9% |
How did E19 perform over the long term?
See historical performance and comparison